A loss of host-derived MMP-7 promotes myeloma growth and osteolytic bone disease in vivo

S. T. Lwin, J. A. Fowler, Matthew M Drake, J. R. Edwards, C. C. Lynch, C. M. Edwards

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Matrix metalloproteinases (MMPs) play a critical role in cancer pathogenesis, including tumor growth and osteolysis within the bone marrow microenvironment. However, the anti-tumor effects of MMPs are poorly understood, yet have significant implications for the therapeutic potential of targeting MMPs. Host derived MMP-7 has previously been shown to support the growth of bone metastatic breast and prostate cancer. In contrast and underscoring the complexity of MMP biology, here we identified a tumor-suppressive role for host MMP-7 in the progression of multiple myeloma in vivo. An increase in tumor burden and osteolytic bone disease was observed in myeloma-bearing MMP-7 deficient mice, as compared to wild-type controls. We observed that systemic MMP-7 activity was reduced in tumor-bearing mice and, in patients with multiple myeloma this reduced activity was concomitant with increased levels of the endogenous MMP inhibitor, tissue inhibitor of metalloproteinases-1 (TIMP-1). Our studies have identified an unexpected tumour-suppressive role for host-derived MMP-7 in myeloma bone disease in vivo, and highlight the importance of elucidating the effect of individual MMPs in a disease-specific context.

Original languageEnglish (US)
Number of pages1
JournalMolecular Cancer
Volume16
Issue number1
DOIs
StatePublished - Feb 28 2017
Externally publishedYes

Fingerprint

Matrix Metalloproteinase 7
Bone Diseases
Matrix Metalloproteinases
Growth
Neoplasms
Multiple Myeloma
Osteolysis
Tissue Inhibitor of Metalloproteinase-1
Matrix Metalloproteinase Inhibitors
Bone Development
Tumor Burden
Prostatic Neoplasms
Bone Marrow
Breast Neoplasms

Keywords

  • Bone
  • Bone disease
  • Microenvironment
  • MMP-7
  • Mouse model
  • Multiple myeloma
  • Osteoclast

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Cancer Research

Cite this

A loss of host-derived MMP-7 promotes myeloma growth and osteolytic bone disease in vivo. / Lwin, S. T.; Fowler, J. A.; Drake, Matthew M; Edwards, J. R.; Lynch, C. C.; Edwards, C. M.

In: Molecular Cancer, Vol. 16, No. 1, 28.02.2017.

Research output: Contribution to journalArticle

Lwin, S. T. ; Fowler, J. A. ; Drake, Matthew M ; Edwards, J. R. ; Lynch, C. C. ; Edwards, C. M. / A loss of host-derived MMP-7 promotes myeloma growth and osteolytic bone disease in vivo. In: Molecular Cancer. 2017 ; Vol. 16, No. 1.
@article{70ae15821b4742439b4890d3219ef030,
title = "A loss of host-derived MMP-7 promotes myeloma growth and osteolytic bone disease in vivo",
abstract = "Matrix metalloproteinases (MMPs) play a critical role in cancer pathogenesis, including tumor growth and osteolysis within the bone marrow microenvironment. However, the anti-tumor effects of MMPs are poorly understood, yet have significant implications for the therapeutic potential of targeting MMPs. Host derived MMP-7 has previously been shown to support the growth of bone metastatic breast and prostate cancer. In contrast and underscoring the complexity of MMP biology, here we identified a tumor-suppressive role for host MMP-7 in the progression of multiple myeloma in vivo. An increase in tumor burden and osteolytic bone disease was observed in myeloma-bearing MMP-7 deficient mice, as compared to wild-type controls. We observed that systemic MMP-7 activity was reduced in tumor-bearing mice and, in patients with multiple myeloma this reduced activity was concomitant with increased levels of the endogenous MMP inhibitor, tissue inhibitor of metalloproteinases-1 (TIMP-1). Our studies have identified an unexpected tumour-suppressive role for host-derived MMP-7 in myeloma bone disease in vivo, and highlight the importance of elucidating the effect of individual MMPs in a disease-specific context.",
keywords = "Bone, Bone disease, Microenvironment, MMP-7, Mouse model, Multiple myeloma, Osteoclast",
author = "Lwin, {S. T.} and Fowler, {J. A.} and Drake, {Matthew M} and Edwards, {J. R.} and Lynch, {C. C.} and Edwards, {C. M.}",
year = "2017",
month = "2",
day = "28",
doi = "10.1186/s12943-017-0616-9",
language = "English (US)",
volume = "16",
journal = "Molecular Cancer",
issn = "1476-4598",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - A loss of host-derived MMP-7 promotes myeloma growth and osteolytic bone disease in vivo

AU - Lwin, S. T.

AU - Fowler, J. A.

AU - Drake, Matthew M

AU - Edwards, J. R.

AU - Lynch, C. C.

AU - Edwards, C. M.

PY - 2017/2/28

Y1 - 2017/2/28

N2 - Matrix metalloproteinases (MMPs) play a critical role in cancer pathogenesis, including tumor growth and osteolysis within the bone marrow microenvironment. However, the anti-tumor effects of MMPs are poorly understood, yet have significant implications for the therapeutic potential of targeting MMPs. Host derived MMP-7 has previously been shown to support the growth of bone metastatic breast and prostate cancer. In contrast and underscoring the complexity of MMP biology, here we identified a tumor-suppressive role for host MMP-7 in the progression of multiple myeloma in vivo. An increase in tumor burden and osteolytic bone disease was observed in myeloma-bearing MMP-7 deficient mice, as compared to wild-type controls. We observed that systemic MMP-7 activity was reduced in tumor-bearing mice and, in patients with multiple myeloma this reduced activity was concomitant with increased levels of the endogenous MMP inhibitor, tissue inhibitor of metalloproteinases-1 (TIMP-1). Our studies have identified an unexpected tumour-suppressive role for host-derived MMP-7 in myeloma bone disease in vivo, and highlight the importance of elucidating the effect of individual MMPs in a disease-specific context.

AB - Matrix metalloproteinases (MMPs) play a critical role in cancer pathogenesis, including tumor growth and osteolysis within the bone marrow microenvironment. However, the anti-tumor effects of MMPs are poorly understood, yet have significant implications for the therapeutic potential of targeting MMPs. Host derived MMP-7 has previously been shown to support the growth of bone metastatic breast and prostate cancer. In contrast and underscoring the complexity of MMP biology, here we identified a tumor-suppressive role for host MMP-7 in the progression of multiple myeloma in vivo. An increase in tumor burden and osteolytic bone disease was observed in myeloma-bearing MMP-7 deficient mice, as compared to wild-type controls. We observed that systemic MMP-7 activity was reduced in tumor-bearing mice and, in patients with multiple myeloma this reduced activity was concomitant with increased levels of the endogenous MMP inhibitor, tissue inhibitor of metalloproteinases-1 (TIMP-1). Our studies have identified an unexpected tumour-suppressive role for host-derived MMP-7 in myeloma bone disease in vivo, and highlight the importance of elucidating the effect of individual MMPs in a disease-specific context.

KW - Bone

KW - Bone disease

KW - Microenvironment

KW - MMP-7

KW - Mouse model

KW - Multiple myeloma

KW - Osteoclast

UR - http://www.scopus.com/inward/record.url?scp=85033494329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033494329&partnerID=8YFLogxK

U2 - 10.1186/s12943-017-0616-9

DO - 10.1186/s12943-017-0616-9

M3 - Article

VL - 16

JO - Molecular Cancer

JF - Molecular Cancer

SN - 1476-4598

IS - 1

ER -